Hikari Power Ltd acquired a new position in shares of Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 200,000 shares of the biotechnology company’s stock, valued at approximately $1,472,000. Hikari Power Ltd owned 0.28% of Progenics Pharmaceuticals as of its most recent SEC filing.

Several other institutional investors also recently made changes to their positions in PGNX. BlackRock Inc. grew its stake in shares of Progenics Pharmaceuticals by 149,468.9% during the first quarter. BlackRock Inc. now owns 9,523,053 shares of the biotechnology company’s stock worth $89,897,000 after purchasing an additional 9,516,686 shares during the period. Eagle Asset Management Inc. grew its stake in shares of Progenics Pharmaceuticals by 50.8% during the second quarter. Eagle Asset Management Inc. now owns 4,012,366 shares of the biotechnology company’s stock worth $27,243,000 after purchasing an additional 1,352,245 shares during the period. Vanguard Group Inc. grew its stake in shares of Progenics Pharmaceuticals by 46.1% during the first quarter. Vanguard Group Inc. now owns 4,132,770 shares of the biotechnology company’s stock worth $39,013,000 after purchasing an additional 1,304,487 shares during the period. State Street Corp grew its stake in Progenics Pharmaceuticals by 42.7% in the second quarter. State Street Corp now owns 3,708,788 shares of the biotechnology company’s stock valued at $25,186,000 after acquiring an additional 1,110,067 shares during the period. Finally, Goldman Sachs Group Inc. grew its stake in Progenics Pharmaceuticals by 207.8% in the first quarter. Goldman Sachs Group Inc. now owns 834,742 shares of the biotechnology company’s stock valued at $7,880,000 after acquiring an additional 563,534 shares during the period. 89.19% of the stock is owned by institutional investors and hedge funds.

PGNX has been the subject of a number of research analyst reports. Cantor Fitzgerald reissued a “buy” rating and issued a $15.00 target price on shares of Progenics Pharmaceuticals in a research note on Thursday, November 2nd. ValuEngine cut Progenics Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, October 6th. Aegis reissued a “buy” rating and issued a $14.00 target price on shares of Progenics Pharmaceuticals in a research note on Tuesday, August 22nd. Zacks Investment Research cut Progenics Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, November 8th. Finally, Needham & Company LLC reissued a “strong-buy” rating and issued a $14.00 target price on shares of Progenics Pharmaceuticals in a research note on Friday, September 1st. Three analysts have rated the stock with a sell rating, four have assigned a buy rating and one has issued a strong buy rating to the company. Progenics Pharmaceuticals presently has a consensus rating of “Hold” and a consensus price target of $13.20.

TRADEMARK VIOLATION WARNING: This report was first published by Watch List News and is owned by of Watch List News. If you are reading this report on another website, it was illegally stolen and reposted in violation of United States and international trademark and copyright laws. The legal version of this report can be read at https://www.watchlistnews.com/hikari-power-ltd-acquires-shares-of-200000-progenics-pharmaceuticals-inc-pgnx/1710093.html.

Progenics Pharmaceuticals, Inc. (PGNX) traded up $0.24 during mid-day trading on Friday, hitting $5.64. The stock had a trading volume of 752,400 shares, compared to its average volume of 1,104,299. The company has a quick ratio of 7.86, a current ratio of 7.86 and a debt-to-equity ratio of 0.80. Progenics Pharmaceuticals, Inc. has a 52 week low of $4.60 and a 52 week high of $11.72.

Progenics Pharmaceuticals (NASDAQ:PGNX) last posted its quarterly earnings data on Thursday, November 2nd. The biotechnology company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.24) by $0.02. The company had revenue of $2.70 million during the quarter, compared to analysts’ expectations of $3.58 million. Progenics Pharmaceuticals had a negative return on equity of 67.61% and a negative net margin of 445.81%. Progenics Pharmaceuticals’s revenue for the quarter was down 95.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.52 earnings per share. equities research analysts anticipate that Progenics Pharmaceuticals, Inc. will post -0.92 EPS for the current fiscal year.

Progenics Pharmaceuticals Company Profile

Progenics Pharmaceuticals, Inc is engaged in developing medicines and other products for targeting and treating cancer. The Company’s pipeline includes therapeutic agents designed to target cancer (AZEDRA and 1095); prostate specific membrane antigen (PSMA)-targeted imaging agents for prostate cancer (1404 and PyL), and imaging analysis tools.

Want to see what other hedge funds are holding PGNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX).

Institutional Ownership by Quarter for Progenics Pharmaceuticals (NASDAQ:PGNX)

Receive News & Ratings for Progenics Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progenics Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.